Cem dias de monitoramento de pacientes submetidos ao transplante de células-tronco hematopoéticas-. eventos da síndrome metabólica
DOI:
https://doi.org/10.24220/2318-0897v23n1a2412Palavras-chave:
Composição corporal, Transplante de células-tronco hematopoéticas, Lipídeos, Síndrome metabólicaResumo
Objetivo
Este estudo avaliou as manifestações precoces de fatores determinantes da síndrome metabólica em pacientes com transplante de células-tronco hematopoéticas.
Métodos
Vinte e sete indivíduos participaram do estudo (20 autólogos e 7 alogênicos). Variáveis antropométricas e indicadores bioquímicos do metabolismo gÊicídico e lipídico foram determinados antes e após 100 dias do transplante.
Resultados
A média de colesterol total (p=0, 086), lipoproteínas de muito baixa densidade-colesterol
(p=0.069) e triglicerides (p=0.086) de todos os pacientes não sofreu alteração significativa entre os dois perídos, porém, quando os pacientes foram separados pelo tipo de transplante de células-tronco hematopoéticas, os triglicerídeos e o lipoproteínas de muito baixa densidade-colesterol apresentaram-se próximos do nível crítico de significância para os indivíduos com transplante alogênico (p=0,06) e o colesterol total aumentou significativamente entre os indivíduos autólogos (p=0.027). As variáveis antropométricas não alteraram significativamente na comparação antes e após transpíante de células-tronco hematopoéticas.
Conclusão
Os fatores de risco para síndrome metabólica podem ser associados com o metabolismo de lipídios na fase inicial do transplante alogênico e autófogo.
Downloads
Referências
Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL. Metabolic syndrome in patients with hematological diseases. Expert Rev Hematol. 2012; 5(4):439-58.
Annaloro C, Onida F, Saporiti G, Lambertenghi Deliliers G. Cancer stem cells in hematological disorders: Current and possible new therapeutic approaches. Curr Pharm Biotechnol. 2011; 12(2):217-25.
Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, Orsatti A, et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(9):797-804.
Federation ID. The IDF consensus worldwide definition of the metabolic syndrome. Belgium: International Diabetes Federation; 2006.
Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: The Norwegian HUNT 2 study. BMC Public Health. 2007; 7:220.
Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, Gonzalez-Sanchez JL, Seclen S, Villena A, et al. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care. 2006; 29(3):685-91.
Mannucci E, Monami M, Cresci B, Pala L, Bardini G, Petracca MG, et al. National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno a Ripoli study. Diabetes Obesity Metabol. 2008; 10(5):430-5.
Mertens I, Van Gaal LF. New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J Thrombosis Haemostasis. 2006; 4(5):1164-6.
Nawabzad R, Champin B. [Concordance between three definitions for metabolic syndrome (Hypertriglyceridemic waist, National Cholesterol Education Program, International Diabetes Federation), and prevalence of the syndrome in a French population]. Rev Prat. 2010; 60(10 Suppl):15-23.
Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease? Intern J Preventive Medicine. 2012; 3(8):552-8.
Rodriguez A, Delgado-Cohen H, Reviriego J, Serrano-Rios M. Risk factors associated with metabolic syndrome in type 2 diabetes Mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions. Diabetes Metab Syndr Obes. 2011; 4:1-4.
Yoon YS, Lee ES, Park C, Lee S, Oh SW. The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: The Korea NHANES study. Inter J Obesity. 2007; 31(3):528-34.
Martin-Salces M, de Paz R, Canales MA, Mesejo A, Hernandez-Navarro F. Nutritional recommendations in hematopoietic stem cell transplantation. Nutrition. 2008; 24(7-8):769-75.
Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplan. 2009; 43(1):49-54.
Baker KS, Armenian S, Bhatia S. Long-term consequences of hematopoietic stem cell transplantation: Current state of the science. Biol Blood Marrow Transplant. 2010; 16(1 Suppl):S90-6.
Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(5):619-25.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143-238.
Nagao K, Yanagita T. Bioactive lipids in metabolic syndrome. Progress Lipid Res. 2008; 47(2):127-46.
